Skip to main content
. 2023 Jul 28;14:4551. doi: 10.1038/s41467-023-40272-3

Fig. 3. Administration of ARVAC CG booster increases the nAb titers against the Ancestral, Gamma, Delta, Omicron BA.1 and Omicron BA.5 variants of SARS-CoV-2.

Fig. 3

The nAb titers against the Ancestral, Gamma, Delta and Omicron BA.1 and Omicron BA.5 variants of SARS-CoV-2 in plasma samples of individuals boosted with ARVAC CG 25 µg (N = 60 individuals) (a) or 50 µg (N = 20 individuals) (b) prior to the vaccine administration (d1) or after 14 days of booster administration (d14). Each point represents the nAb titer of a volunteer at the indicated time point and against the depicted viral variant. The nAb geometric mean titers (GMTs) and 95% CIs are shown as horizontal and error bars, respectively. The numbers depicted above the individual points for each specified time point and viral variant represent de GMT. The fold increase in the GMT from day 1 to day 14 (GMFR) for each specified variant are shown with a number followed by a ×. The dashed line represents the positivity threshold on the virus neutralization assay. Statistical differences were analyzed using the two-tailed Wilcoxon pair-matched test. P-values are depicted above the data sets that were compared. In panel (a) all P values were smaller than 10e-15; in panel (b) P = 0.000004 for Ancestral strain, Gamma and Omicron BA.1 VOCs, P = 0.000099 for Delta VOC and P = 0.000015 for Omicron BA.5.